Protocol REVERSE-Long COVID-19 With Baricitinib Study (REVERSE-LC)
- Thread starter EndME
- Start date
From Chat GPT video summarizer (not sure how this works, but it works!)
### Summary of "Prof. E. Wesley Ely: Immunomodulation in Long Covid (Day 1, Block 4)"
- **Introduction and Speaker Background**:
- Dr. Wes Ely, a leading internist, pulmonologist, and critical care physician at Vanderbilt University.
- Co-director of the Critical Illness, Brain Dysfunction, and Survivorship Center.
- Notable research on ICU-acquired brain disease and delirium.
- **Presentation Highlights**:
- Dr. Ely discusses the Reverse LC Study, focusing on immunomodulation as a pathway to discovery for long Covid.
- Describes the story of a young man, a post-graduate student and near-concert pianist, who developed severe long Covid symptoms affecting his daily life and academic pursuits.
- **Long Covid and Research Efforts**:
- Emphasizes the importance of not abandoning long Covid patients and accompanying them with the best science.
- Discusses involvement in the National Academy of Medicine's efforts to redefine long Covid and improve research definitions.
- **Reverse LC Clinical Trial**:
- Details about the Phase III NIH-sponsored clinical trial of immunomodulation in long Covid.
- Enrollment to begin soon, with sites including Minnesota, Nashville, Emory in Atlanta, and UCSF.
- Collaboration with notable scientists like Akiko Iwasaki from Yale.
- **Historical Context and Drug Development**:
- Origin of the study from early AI predictions identifying baricitinib as a potential treatment for acute Covid.
- Previous successful trials showing baricitinib's effectiveness when combined with steroids in improving survival rates.
- **Trial Specifics**:
- Involves a high-touch study with comprehensive testing and patient monitoring.
- Patients will receive either placebo or baricitinib daily for six months and will be followed for a year.
- Aimed at understanding the effects of immunomodulation on brain fog and other long Covid symptoms.
- **Scientific Rationale**:
- Baricitinib’s role as an antiviral and immunomodulator, impacting various immune system components.
- The trial seeks to determine if this drug can alleviate symptoms by modulating the immune response without significant risks.
- **Ethics and Future Research**:
- Emphasis on conducting the study without financial conflicts of interest.
- Future plans to explore additional studies, including those involving Metformin.
- **Q&A Session**:
- Discussion on topics such as viral replication, interferon therapy, and inclusion of post-vaccine syndrome patients in future studies.
For more information, visit the [UniteToFight channel](https://www.youtube.com/UniteToFight).
---
If you found this summary useful, please consider sharing it with others. Doing so will help GPT reach more people and continue to improve. Thank you!
[Click here to share GPT on Twitter / X](https://bit.ly/3SbQ7jI)
### Summary of "Prof. E. Wesley Ely: Immunomodulation in Long Covid (Day 1, Block 4)"
- **Introduction and Speaker Background**:
- Dr. Wes Ely, a leading internist, pulmonologist, and critical care physician at Vanderbilt University.
- Co-director of the Critical Illness, Brain Dysfunction, and Survivorship Center.
- Notable research on ICU-acquired brain disease and delirium.
- **Presentation Highlights**:
- Dr. Ely discusses the Reverse LC Study, focusing on immunomodulation as a pathway to discovery for long Covid.
- Describes the story of a young man, a post-graduate student and near-concert pianist, who developed severe long Covid symptoms affecting his daily life and academic pursuits.
- **Long Covid and Research Efforts**:
- Emphasizes the importance of not abandoning long Covid patients and accompanying them with the best science.
- Discusses involvement in the National Academy of Medicine's efforts to redefine long Covid and improve research definitions.
- **Reverse LC Clinical Trial**:
- Details about the Phase III NIH-sponsored clinical trial of immunomodulation in long Covid.
- Enrollment to begin soon, with sites including Minnesota, Nashville, Emory in Atlanta, and UCSF.
- Collaboration with notable scientists like Akiko Iwasaki from Yale.
- **Historical Context and Drug Development**:
- Origin of the study from early AI predictions identifying baricitinib as a potential treatment for acute Covid.
- Previous successful trials showing baricitinib's effectiveness when combined with steroids in improving survival rates.
- **Trial Specifics**:
- Involves a high-touch study with comprehensive testing and patient monitoring.
- Patients will receive either placebo or baricitinib daily for six months and will be followed for a year.
- Aimed at understanding the effects of immunomodulation on brain fog and other long Covid symptoms.
- **Scientific Rationale**:
- Baricitinib’s role as an antiviral and immunomodulator, impacting various immune system components.
- The trial seeks to determine if this drug can alleviate symptoms by modulating the immune response without significant risks.
- **Ethics and Future Research**:
- Emphasis on conducting the study without financial conflicts of interest.
- Future plans to explore additional studies, including those involving Metformin.
- **Q&A Session**:
- Discussion on topics such as viral replication, interferon therapy, and inclusion of post-vaccine syndrome patients in future studies.
For more information, visit the [UniteToFight channel](https://www.youtube.com/UniteToFight).
---
If you found this summary useful, please consider sharing it with others. Doing so will help GPT reach more people and continue to improve. Thank you!
[Click here to share GPT on Twitter / X](https://bit.ly/3SbQ7jI)
Utsikt
Senior Member (Voting Rights)
Covid has it’s own host of cognitive problems ik addition to the normal ME/CFS ones. Many people experience lasting cognitive symptoms without being close to an ME/CFS diagnosis, and some patients with severe ME/CFS due to Covid are doing fine cognitively (including myself). I get brainfog from exertion, but I’ve done extensive tests that were completely fine.
Also being Uk based makes me think what feels often like a concerted campaign to ensure me/cfs patients don’t get in front of any biomedical clinicians ever nevermind clinics taking long term responsibility as is the standard for other things .. well is partly about stunting this type of thing being able to be requested or happen.
which is silly because long term whatever ends up helping is highly likely to be cheaper in total than the bps kingdoms they’ve built, nevermind the rubble left in their wake due to the added disability they created with bigotry and unnecessary worsening + the disability that could have at least been prevented from getting worse with basic medical care and the odd adjustments
good to see it happening for LC I guess